Company intelligence / Profile preview
Immatics
- Ownership
- Public · IMTX
- Employees
- ~700
- Development stage
- Phase 3
Overview
Immatics has multiple clinical programs including IMA901 (Phase 3 for renal cell carcinoma), IMA910 (completed Phase 1/2 for colorectal carcinoma), IMA950 (Phase 1 for brain cancer), and newer programs like IMA101, IMA201, IMA202, IMA203, and IMA301. Recently announced first clinical data on TCER® IMA402 targeting PRAME.
- Therapeutic areas
- Oncology
- Modalities
- TCR-T (T cell receptor-engineered T cell)TCR Bispecifics (TCER®)Adoptive Cell Therapies (ACT)Therapeutic Vaccines
- Industry
- Biotech
Drug pipeline
16 assets15 more assets in the full pipeline.
Partnerships
Financials
- Market cap
- $951.7M
- Total revenue
- $53.8M
- Enterprise value
- $529.6M
Beyond the preview
Go deeper on Immatics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immatics.